Tests telisotuzumab adizutecan with an immunotherapy drug in lung cancer
Tests a new drug with pembrolizumab in adults with advanced non-squamous lung cancer.
Plain-language title generated from the registry record
Registry title: Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Key facts
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Kunming, Liuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, and Zhengzhou, ChinaSee the 15 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spread non-squamous non-small cell lung cancer who have had little or no earlier drug treatment for advanced disease.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Non-squamous non-small cell lung cancer (NSCLC) that is locally advanced or has spread (metastatic), with disease that can be measured on scans (RECIST v1.1).
- Earlier treatment
- Part 1: no more than 1 earlier systemic therapy for advanced disease. Part 2: no earlier systemic therapy for advanced disease.
- Biomarker or test result
- PD-L1 status must be documented. Part 2: no known actionable genomic alteration, and a c-Met immunohistochemistry (IHC) result from central testing before randomization.
Main reasons for not taking part
- Known uncontrolled metastases to the central nervous system
- History of interstitial lung disease (ILD) or pneumonitis that needed systemic steroids
- Any sign of active ILD or pneumonitis on the screening chest CT scan
Read by machine on 9 November 2026.
Where in China
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715Beijing, ChinaTaking people
- Hunan Province Cancer Hospital /ID# 269679Changsha, ChinaTaking people
- Sichuan Province Cancer Hospital /ID# 269712Chengdu, ChinaTaking people
- West China Hospital of Sichuan University /ID# 270244Chengdu, ChinaTaking people
- Fujian Province Cancer Hospital /ID# 269150Fuzhou, ChinaTaking people
- Yunnan Province Cancer Hospital /ID# 272331Kunming, ChinaTaking people
- Liuzhou People's hospital /ID# 269667Liuzhou, ChinaTaking people
- The First Affiliated Hospital of Nanchang University /ID# 269190Nanchang, ChinaTaking people
- Nanjing Drum Tower Hospital /ID# 269762Nanjing, ChinaTaking people
- Shanghai Chest Hospital /ID# 269155Shanghai, ChinaTaking people
- Shanghai Pulmonary Hospital /ID# 276397Shanghai, ChinaTaking people
- First Affiliated Hospital of Shanxi Medical University /ID# 276482Taiyuan, ChinaTaking people
- Union Hospital - Tongji Medical College /ID# 272286Wuhan, ChinaTaking people
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904Xi'an, ChinaTaking people
- Henan Cancer Hospital /ID# 269668Zhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT06772623EU 2024-514465-18-00
- Record updated
- 27 October 2026
- Original description
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.Read full original descriptionShow less
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Inclusion: Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study; Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1; For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC; For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration; Must have documented programmed death ligand 1 (PD-L1) status; For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization; Must have adequate organ function.
Exclusion: History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan; Known uncontrolled metastases to the central nervous system.